1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 10
1.3 Pest Analysis 11
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Total Addressable Market (TAM) 14
3.2 Disease Overview 15
3.2.1 Hepatitis A 15
3.2.1.1 Epidemiology 15
3.2.1.2 Therapy 15
3.2.2 Hepatitis B 15
3.2.2.1 Epidemiology 15
3.2.2.2 Therapy 16
3.2.3 Hepatitis C 16
3.2.3.1 Epidemiology 16
3.2.3.2 Therapy 17
3.2.4 Hepatitis D 18
3.2.5 Hepatitis E 19
3.3 Disease Transmission 19
3.4 Related Markets 20
4 Market Outlook 21
4.1 Overview 21
4.2 Regulatory Bodies & Standards 21
4.3 Porter 5 (Five) Forces 22
5 Market Characteristics 23
5.1 Evolution 23
5.2 ROADMAP 24
5.3 Market Dynamics 25
5.3.1 Drivers 25
5.3.1.1 Increasing Demand of Hepatitis Drugs 25
5.3.1.2 Focus on Advanced DAAs 25
5.3.1.3 Introduction of IFN-free Therapies 26
5.3.1.4 Growth of Injection Drug Users 26
5.3.2 Restraints 27
5.3.2.1 Long Approval Process and Stringent Regulations 27
5.3.2.2 Side Effects of Hepatitis Drugs 27
5.3.2.3 Increase in the Number of Generic Drugs 27
5.3.2.4 Increasing Market Competition 27
5.3.3 Opportunities 28
5.3.3.1 Significant Increase in Mergers and Acquisitions 28
5.3.3.2 Emergence of Combination Drugs 28
5.3.3.3 Preventive Healthcare 28
5.3.3.4 Focus of Companies on Emerging Market 29
5.3.4 DRO - Impact Analysis 29
6 Trends' Roadmap and Projects 30
6.1 Market Trends & Impact 30
6.2 Technology Roadmap 31
7 Types: Market Size & Analysis 32
7.1 Overview 32
7.2 Hepatitis A Segment 33
7.3 Hepatitis B Segment 34
7.4 Hepatitis C Segment 34
8 Trending Hepatitis Drugs 36
8.1 Overview 36
8.1.1 VEMLIDY 37
8.1.2 EPCLUSA 37
8.1.3 SOVALDI 37
8.1.4 INCIVEK 38
8.1.5 OLYSIO 38
8.1.6 VICTRELIS 38
8.1.7 VIREAD 38
8.1.8 HEPSERA 38
8.1.9 BARACLUDE 39
8.1.10 TYZEKA 39
8.1.11 INTRON A 39
8.1.12 PEGASYS 39
8.1.13 PEGINTRON 40
8.1.14 ROFERON-A 40
8.1.15 VIRAFERONPEG 40
8.1.16 REBETOL 40
9 Regions: Market Size & Analysis 41
9.1 OVERVIEW 41
9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation 42
10 Vendor Scenario 43
10.1 Market Share Ranking 2016 44
10.1.1 GILEAD SCIENCES INC. 44
10.1.1.1 Sovaldi (sofosbuvir) 44
10.1.1.2 Harvoni (ledipasvir and sofosbuvir) 44
10.1.1.3 Viread (tenofovir disoproxil fumarate) 45
10.1.1.4 Hepsera (adefovir dipivoxil) 45
10.1.2 ABBVIE INC. 45
10.1.2.1 Viekira Pak (ombitasvir' paritaprevir' ritonavir and dasabuvir) 45
10.1.3 JOHNSON & JOHNSON 46
10.1.3.1 Olysio (simeprevir) 46
10.1.3.2 Incivo(telaprevir) 46
10.1.4 MERCK & CO. INC. 46
10.1.4.1 Zepatier (elbasvir and grazoprevir) 46
10.1.4.2 Victrelis (boceprevir) 47
10.1.4.3 Peg-Intron (peginterferon alfa-2b) 47
10.1.4.4 Rebetol (ribavirin) 47
10.1.4.5 Intron A (interferon alfa-2b' recombinant) 47
10.1.5 GLAXOSMITHKLINE PLC 48
10.1.5.1 Pediarix Vaccine 48
10.1.5.2 Twinrix 48
10.1.5.3 Havrix 48
10.1.5.4 Epivir (lamivudine) 48
10.1.6 VERTEX PHARMACEUTICALS INC. 48
10.1.6.1 Incivek (telaprevir) 48
10.1.7 NOVARTIS AG 49
10.1.7.1 Tyzeka (telbivudine) 49
10.1.8 HOFFMANN-LA ROCHE LTD. 49
10.1.8.1 Pegasys (peginterferon alfa-2a) 49
11 Vendor Profiles 50
11.1.1 Merck & Co. Inc. 50
11.1.1.1 Overview 50
11.1.1.2 Business unit 51
11.1.1.3 Geographic revenue 52
11.1.1.4 Recent developments 53
11.1.1.5 SWOT analysis 54
11.1.1.6 Business strategies 55
11.1.2 Hoffmann-La Roche Ltd. 56
11.1.2.1 Overview 56
11.1.2.2 Business Unit 57
11.1.2.3 Geographic revenue 58
11.1.2.4 Recent developments 58
11.1.2.5 SWOT analysis 60
11.1.2.6 Business strategies 60
11.1.3 Gilead Sciences 62
11.1.3.1 Overview 62
11.1.3.2 Business Unit 63
11.1.3.3 Geographic revenue 65
11.1.3.4 Recent developments 65
11.1.3.5 SWOT analysis 66
11.1.3.6 Business strategies 66
11.1.4 Novartis AG 67
11.1.4.1 Overview 67
11.1.4.2 Business Unit 67
11.1.4.3 Geographic revenue 69
11.1.4.4 Recent developments 69
11.1.4.5 SWOT analysis 71
11.1.4.6 Business strategies 71
11.1.5 GlaxoSmithKline plc 72
11.1.5.1 Overview 72
11.1.5.2 Business Unit 73
11.1.5.3 Geographic revenue 75
11.1.5.4 Recent developments 75
11.1.5.5 SWOT analysis 76
11.1.5.6 Business strategies 77
12 Global Generalist 78
12.1 Vertex Pharmaceuticals Inc. 78
12.1.1 Overview 78
12.1.1.1 Recent developments 79
12.1.2 Vertex Pharmaceuticals Inc. in 2015 80
12.2 Johnson & Johnson 81
12.2.1 Overview 81
12.2.1.1 Recent developments 82
12.2.2 Johnson & Johnson in 2015 83
13 Market Landscape 85
13.1 Market Landscape 85
13.1.1 Mergers & Acquisitions (M&A) 85
Annexure 87
? Acronyms 87